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Synthesis and secretion of transforming growth factor beta isoforms by
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Summary Tamoxifen may mediate its effect in early breast cancer in part via an oestrogen receptor (ER)-
independent pathway by directly stimulating fibroblasts to produce the negative paracrine growth factor
transforming growth factor (TGF)-f,. We have previously shown that secretion of this factor is induced 3-to 30-
fold in human fetal fibroblasts in vitro, and by stromal fibroblasts in vivo following tamoxifen treatment of ER-
positive and ER-negative breast cancer patients. Primary cultures of breast tumour fibroblasts have been
exposed to tamoxifen for 48 h, and rates of secretion of TGF-fl, and TGF-fl2 measured using a quantitative
immunoassay. Fibroblast strains derived from malignant and benign tumours produced and secreted similar
amounts of TGF-flp, but benign breast tumour fibroblasts secreted significantly higher levels of TGF-f32
compared with fibroblasts of malignant origin. Tamoxifen did not induce any consistent increase in TGF-,B
secretion into the conditioned medium, but immunofluorescence analysis for the intracellular form ofTGF-f3,
revealed evidence ofincreased immunoreactive protein in tamoxifen-treated fibroblasts, which is localised to the
nucleus. Therefore synthesis ofTGF-fl, appears to be stimulated by tamoxifen, but increased secretion may be
abrogated in vitro. Furthermore, using immunocytochemistry and transient transfection with an ER-responsive
reporter construct, no ER was demonstrable in these fibroblasts supporting the proposed ER-independent
paracrine pathway.
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Initial results from the Nolvadex Adjuvant Trial Organisa-
tion (NATO) (1988) and Medical Research Council Scottish
trials (1987) revealed that the efficacy of adjuvant tamoxifen
in early breast cancer appeared to be independent of
oestrogen receptor (ER) status. In the 8 year analysis of
the NATO trial, division of patients according to ER status
did not eliminate the favourable effects of tamoxifen
treatment, and multivariate regression analysis did not show
any significant difference in treatment effect between ER-
positive and ER-negative patients. The more recent overview
by the Early Breast Cancer Trialists Collaborative Group
(1992) confirmed that ER status fails to select a group of
patients who will not benefit from adjuvant tamoxifen
therapy, and in particular reaffirmed that ER-negative
patients obtain unequivocal benefit.
These counterintuitive results are difficult to reconcile with
the classical mode of action of anti-oestrogens as competitive
antagonists for the ligand binding site of the ER, a
mechanism that is precluded in ER-negative cells (Terenius,
1968). It was therefore proposed that tamoxifen directly
stimulates fibroblasts to produce and secrete negative growth
modulators, which act upon neighbouring malignant
epithelial cells in a negative paracrine manner (Colletta et
al., 1990). Certain other observations contributed to
formulation of this hypothesis; firstly, the timing of
androgen receptor expression in the mesenchyme of the
developing rodent prostate-androgen receptors are expressed
on the mesenchyme of hormonally sensitive tissues before
their expression of epithelial cells, implying that hormones
can act indirectly upon epithelium (Cunha and Donjacour,
1987). Secondly, skin fibroblasts from patients with a family
history of breast cancer display fetal-like characteristics, thus
alluding to some systemic abnormality of fibroblasts (Haggie
et al., 1987). Finally desmoids, which are pure mesenchymal
tumours, undergo dramatic clinical response to tamoxifen
and related triphenylethylenes, implying a direct effect of
these agents upon fibroblasts (Brookes et al., 1992).
There is now evidence for stromal induction of the
negative growth modulator, transforming growth factor
(TGF-f) both in vitro (Colletta et al., 1990) and in vivo (Butta
et al., 1992) in response to tamoxifen. TGF-P is a member of
a superfamily of regulatory peptides, existing as three
isoforms TGF-fl,, TGF-f2 and TGF-#3 in mammalian
species. These are multifunctional peptides that are usually
stimulatory to cells of mesenchymal origin (Roberts et al.,
1981), but inhibitory to certain epithelia (Roberts et al.,
1985). This growth factor is involved in cellular proliferation
and differentiation during development, and defective TGF-P
signalling may be implicated in carcinogenesis (Roberts et al.,
1988). Specific roles for TGF-# in malignant predisposition
and progression have been proposed, owing either to loss of
sensitivity to TGF-# (Tucker et al., 1984) or defective
intrinsic production by stromal cells, leading to reduced
negative paracrine influences upon neighbouring epithelial
cells (Benson and Baum, 1993).
Previous in vivo studies have suggested that stromal
fibroblasts are the source of extracellular TGF-pi, which is
up-regulated following primary tamoxifen therapy of ER-
positive and ER-negative breast cance patients (Butta et al.,
1992). We have further investigated this concept and present
evidence here that breast tumour fibroblasts are a rich source
of TGF-#f and that synthesis of this negative growth factor
can be modulated by tamoxifen, suggesting a mechanism
whereby this agent could augment the negative paracrine
regulation of epithelial proliferation by fibroblasts.
Methods
Primary culture offibroblasts
Primary cultures of fibroblasts were derived from patients
with either malignant (strains A-D) or benign (E-G) breast
tumours. The clinical details of these patients are summarised
in Table I. A further strain (H) was obtained from a skin
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1996Table I Clinicopathological features of patients from whose breast
tumours fibroblast strains were derived
Cell Patient age Pathology Grade Nodal status ER status
strain (years)
A 64 IDC (NOS) PD (III) Unknowna Unknown
B 61 IDC (NOS) MD (II) Negative Negative
C 55 IDC (NOS) PD (III) Negative Positive
D 73 IDC (NOS) MD (II) Positive Negative
E 51 FA - -
F 38 FA - - -
G 60 FC
H 60 Skin
aNo axillary surgery. IDC, infiltrating ductal carcinoma; NOS, type
'not otherwise specified', MD, moderately differentiated; PD; poorly
differentiated, FA, fibroadenoma; FC, fibrocystic disease.
sample of a patient with benign breast disease, and these were
considered to be normal skin fibroblasts. Specimens of tissue,
collected at surgery, were washed immediately in RPMI-1640
medium following collection and excess fat trimmed off.
Specimens were minced into small fragments (2-3 mm) and
digested overnight with collagenase [type IIS (Sigma)
1 Mg ml-'] for a period of 24 h. The resulting cell suspension
was centrifuged (580 g, 10 min) and the pellet was
resuspended in complete medium, consisting of minimal
essential medium (MEM) supplemented with 10% fetal calf
serum (FCS), basic fibroblast growth factor (FGF)
(25 ng ml-1), L-glutamine (2 mM), penicillin (1000
units ml-'), streptomycin (100 Mg ml-1) and fungizone
(25 ng ml-1) (Freshney, 1987). Flasks were incubated at
37°C, 100% humidity and 5% carbon dioxide. Cultures were
left undisturbed for 3-4 days, after which time fibroblasts
were seen to be attaching. Cells were passaged when cultures
reached confluence after 10- 14 days, and fibroblasts used
between passages 5-10.
Verification offibroblast origin
The identity of fibroblasts was confirmed not only by their
characteristic morphology, but also by staining for the
specific immunophenotype. Fibroblasts were seeded into
slide flasks at a density of 105 cells ml-' and grown to 80-
90% confluence, followed by fixation in ice-cold acetone.
Following blocking of non-specific binding sites with 50% (v/
v) porcine serum in phosphate-buffered saline (PBS), cells
were labelled with 5 Mg ml-1 of an anti-vimentin mouse
primary antibody (Boehringer-Mannheim) and identified with
20 Mg ml-' of a secondary anti-mouse antibody conjugated
to rhodamine. To verify that cultures were free from
epithelial contamination, cells were labelled with 20 Mg ml-'
of an anti-keratin primary antibody (ICN Immunobiologi-
cals). Cells were photomicrographed using a BioRad MRC
600 Nikon confocal fluorescence microscope.
Oestrogen receptor content offibroblasts
Transfection of fibroblasts-primary fibroblast strains were
grown to 50-60% confluence in 90 mm petri dishes in phenol
red-free improved minimal essential medium (IMEM),
containing 10% FCS [dextran-coated charcoal (DCC)
treated] (Green and Leake, 1987), FGF, L-glutamine,
antibiotics and fungizone in the above concentrations. Cells
were transiently transfected with the ER-responsive reporter
construct ERE-tk-CAT, consisting of the oestrogen response
element (ERE) (Kumar and Chambon, 1988) linked to a
hymidine kinase promoter and the chloramphenicol acetyl-
transferase (CAT) reporter gene. Transfection was carried out
using Lipofectin (Gibco BRL). As an internal control, cells
were co-transfected with the pCH110 plasmid (Pharmacia),
which contains the fl-galactosidase gene. As a positive control,
cells were in addition triple transfected with the human ER
expression vector pSG5-HEO (hER) (Green et al., 1986). Each
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fibroblast strain was transfected with the ERE-tk-CAT
construct in the presence of either 10 nM oestradiol or 1 gM
tamoxifen. Internal controls were transfected with the pCH1 10
and ERE-tk-CAT constructs in the absence of any ligand, and
positive controls with both ERE-tk-CAT together with hER.
Aliquots of 10 Mg of each type of DNA was added per
dish, i.e. 20 ,g in total except for the positive controls, which
received an additional 10 jug of hER. Cells were exposed to
the lipofectin/DNA complex in serum-free medium for 24 h,
followed by complete medium (containing 10% DCC-treated
serum) for a further period of 48 h, after which cells were
harvested for functional assays. CAT activity was measured
in cell extracts using [3H]acetyl co-enzyme A (0.1 MCi) in a
scintillation-based assay (Neumann et al., 1987). CAT values
were normalised to the fl-galactosidase levels, which were
measured spectrophotometrically (Sambrook et al., 1989).
Secretion of TGF-,B isoforms into conditioned media of
fibroblasts
Fibroblasts were seeded into 25 cm2 flasks in complete serum
containing medium(MEM), and grown to subconfluence. Cells
were washed twice with PBS and complete medium replaced
with serum-free and phenol red-free medium supplemented
with 5 ig ml-' bovine insulin and containing either 1 ,M
tamoxifen or ethanolic vehicle (0.1%, v/v). Conditioned media
(CM) were collected after a period of 48 h into siliconised
vessels, clarified by centrifugation and stored at - 70°C before
sandwich enzyme-linked immunosorbent assay (SELISA). Cell
monolayers were trypsinised, and cells harvested for counting.
For SELISA analysis 1 ml samples of CM were thawed and
treated with a cocktail ofprotease inhibitors to yield 1 Mg ml-
leupeptin, 1 Mg ml-' aprotonin, 1 Mg ml-' pepstatin,
120 Mg ml-1 phenylmethylsulphonyl fluoride (PMSF) and
100 Mg ml-1 bovine serum albumin.
Following precipitation of total protein from CM with
100% w/v trichloroacetic acid (TCA) protein pellets were
washed with ether-ethanol (1:1, v/v) at 4°C and lyophilised
before assay for TGF-/1 and TGF-fl2 using highly specific
SELISAS (Danielpour et al., 1989; Flanders et al., 1990).
Staining offibroblasts for the intracellularform of TGF-f3,
Fibroblasts from breast tumours were grown in slide flasks to
subconfluency in complete medium containing FCS. Cells
were washed twice with PBS and 3 ml of serum-free and
phenol red-free medium containing either 1 gM tamoxifen or
ethanolic vehicle only added. After 48 h, media were
discarded and cells fixed in ice-cold acetone. Non-specific
binding sites were blocked with 50% (v/v) goat serum in PBS.
Cells were exposed to primary polyclonal antibody to the
intracellular form of TGF-,13 (either anti-LC antibody raised
against amino acids 1-30 of the mature TGF-,B, or anti-
precursor peptide raised against amino acids 266-278 of the
TGF-f11 precursor23) at 10 Mg ml-' and incubated at 20°C for
2 h. Bound anti-TGF-f1, antibody was identified using a
secondary anti-rabbit IgG conjugated to the fluorescent
marker Texas red. Cells were mounted in glycerol, contain-




Two fibroblast strains were stained with monoclonal
antibodies to either vimentin or keratin. Figure la shows
one strain (A) labelled with the anti-vimentin antibody. The
majority of cells show strong immunoreactivity, whereas cells
exposed to the secondary antibody show only background
immunofluorescence (data not shown). Breast epithelial cells
such as T47-D cells stain positively for the anti-keratin
antibody, in contrast to cultures of fibroblasts where no
significant staining ofcells is seen (Figure lb). This pattern ofTamoxifen and TGF-f isoforms
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staining together with the characteristic spindle morphology
of the cells confirms their fibroblast origin.
Oestrogen receptor content offibroblast
Figure 2 shows the results of transiently transfecting four
fibroblast strains derived from malignant breast tumours with
an ER-responsive reporter construct. All four cell strains
transfected with hER in the presence of its ligand (positive
control, column 4) produce a high CAT signal, although the
signal for one strain (D) is of relatively lower absolute value.
In contrast, transfection of the ERE-tk-CAT construct
without exogenous ER expression, either in the presence of
E2 (column 2) or tamoxifen (column 3), yields a signal similar
to the vehicle control (column 1).
These results are consistent with absence of ER protein or
other transactivating proteins that function at the ERE from
breast tumour fibroblasts, and are in agreement with our
immunohistochemical examination of these cells for ER,
which shows no specific staining (data not shown). This is in
accordance with our previous data for fetal lung and
pituitary fibroblasts (Colletta et al., 1990) and the data of
others (Peterson et al., 1987).
Secretion of TGF-f3 isoforms into conditioned media of
fibroblasts
The rates of secretion of TGF-f,B and TGF-32 into the
conditioned media of the eight fibroblast strains used in this
study are shown in Table II. These values are the mean rates
of secretion calculated for duplicate samples each based on
either three (TGF-f,1) or two (TGF-f2) determinations, with a









Figure 1 (a and b) Verification of fibroblast 'origin with
immunofluorescence. A representative strain of breast tumour
fibroblasts stained with a monoclonal antibody against vimentin,
a structural protein characteristic of cells of mesenchymal origin.
(a) Cells stained with an anti-vimentin antibody conjugated to the
fluorescent marker rhodamine. Strong cytoplasmic staining is
seen, and cells have the typical spindle morphology of fibroblasts.
(b) Cells stained with an anti-keratin antibody. The characteristic
outline of fibroblasts is discernible, but minimal intracellular
staining is seen.
U
A B C D
Fibroblast cell strain
Figure 2 Measurement of ER content of breast tumour
fibroblasts using transient transfection of an ER-tk-CAT reporter
construct. Four strains of fibroblasts were transfected with the
ERE-tk-CAT construct using Lipofectin. Cells were transfected
either in the presence of E2 or tamoxifen. As an internal control,
all cells were co-transfected with the pCH 11O vector, and as a
positive control, cells were in addition triple transfected with the
hER construct. Cells tranfected with both ERE-tk-CAT and hER
yielded a high CAT signal (column 4), in contrast to cells
transfected with ERE-tk-CAT alone, either in the presence of E2
(column 2) or tamoxifen (column 3), when CAT signals were
similar to the internal controls (column 1). M, pCH1 10 + ERE-
tk-CAT; W, pCHlIO+ERE-tk-CAT+E2; -, pCHllO
+ERE-tk-CAT + tamoxifen; M, pCH 10 + ERE-tk-CAT +
hER+ E2.
Table II Secretion rates of TGF-3,B and TGF-/32 into conditioned media of fibroblasts in presence and absence of tamoxifen
TGF-13 GF,B
(ng 106 48 h-1) TGF-f32
Cell strain Control Tamoxifen Control Tamoxifen
A (malignant) 3.91 +0.23 5.19 ±0.50 0.08±0.00 0.11 +0.00
B (malignant) 1.16+0.13 1.04+0.07 0.07±0.01 0.05±0.00
C (malignant) 3.09 ±0.35 2.83+ 0.18 0.07±0.00 0.07+0.00
D (malignant) 0.84±0.07 1.03 ±0.04 <0.01 <0.01
E (benign) 2.10+0.00 2.68+0.00 0.156+0.02 0.170+0.00
F (benign) 1.06 +0.00 0.78+0.25 0.150+0.00 <0.05
G (benign) 1.28 +0.00 1.10±0.23 1.26+0.13 1.35 +0.06
H (skin) 0.54+0.00 0.57+0.00 <0.05 <0.05
Fibroblasts derived from malignant (strains A-D) or benign (strains E-F) breast tumours, together with a single strain ofskin fibroblasts (H)
were grown to subconfluence in slide flasks and subsequently treated with either 1 ,UM tamoxifen or ethanolic vehicle for a period of 48 h.
Conditioned medium washarvested and totalproteinprecipitated with 100% (w/v) trichloroacetic acid before measurement ofTGF-f,3 andTGF-f32
levels using a sandwich ELISA. Each value is the mean rate of secretion calculated for duplicate samples each based on three (TGF-fl1) or two
(TGF-f32) determinations (lower limit ofdetection 1 pM concentration in sample ofconditioned medium).Tamoxifen and TGF-,B isoforms
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from malignant tumours (A-D) produce and secrete
relatively large amounts of TFG-f., ranging from 0.84 to
3.91 ng 10-6 cells 48 h-', with a mean value of 2.25 ng 10-6
cells 48 h-'. Although absolute levels of TGF-f, vary
between fibroblast strains (up to 6-fold), levels for each
strain are concordant with small standard deviations.
Fibroblasts derived from benign tumours (E-G) secrete
slightly lower levels of TGF-f31, ranging from 1.06 to
2.10 ng 10-6 cells 48 h-' with a mean value of 1.48 ng 10-6
cells 48 h-1. Levels of TGF-fl, secretion are not statistically
significantly different between fibroblasts derived from
malignant vs benign breast tumour fibroblasts. Absolute
levels of secretion by these breast tumour fibroblasts are
higher than for normal skin fibroblasts (H). Levels of
secretion of the f2 isoform by fibroblasts derived from
malignant tumours (A-D) are approximately 50-fold lower
than those of TGF-#3, but fibroblasts from benign tumours
secrete significantly higher levels of TGF-#2 that for one cell
strain (G) approaches that of TGF-fJ1. There is a statistically
significant difference in levels of secretion ofTGF-fJ2 between
benign and malignant breast tumour fibrobasts (P<0.05).
In contrast to fetal fibroblasts, tamoxifen does not induce
any consistent increase in levels ofTGF-#f, although there is
relatively modest increase in secretion of approximately 30%
by strain A in response to tamoxifen. Although levels of
secretion are not generally enhanced by tamoxifen, absolute
rates are 3 to 4-fold higher than basal unstimulated values for
fetal fibroblasts (0.4-0.6 ng 10-6 cells 48 h-', mean
0.5 ng 10-6 cells 48 h-1) (Colletta et al., 1990).
Immunofluorescence offibroblastsfor the intracellularform of
TGF-B13
To further investigate TGF-,B synthesis in these cells, we
employed immunofluorescence microscopy to examine the
intracellular distribution and/or processing of TGF-,B after
tamoxifen treatment. Figure 3 shows fibroblasts from a
malignant breast tumour stained with the anti-LC (1-30)
antibody, which specifically reacts with the intracellular form
ofTGF-fl,1 (Flanders et al., 1989), detected with a fluorescent
secondary antibody. Cells in Figure 3a were treated with
vehicle alone, whereas those in Figure 3b were treated with
I gIM tamoxifen for 48 h before staining. Immunofluorescence
analysis yields a distinctive pattern of staining in the nuclear
region, and tamoxifen treatment of fibroblasts dramatically
increases the intensity of this immunofluorescence (Figure
3b). This response was observed in all strains of breast
tumour fibroblasts tested, together with A549 cells, which are
known to be a rich source ofTGF-fl, (Flanders et al., 1989).
Optical sectioning experiments in which confocal images are
taken sequentially through the image plane indicate that this
staining is indeed nuclear, and not confined to a peri-nuclear
structure (Figure 4). To further confirm that the observed
staining is attributable to TGF-#,, the same fibroblasts have
been stained with an antibody raised to the precursor region
of TGF-fl, (Flanders et al., 1989). This antibody gives a
broadly similar pattern of staining, and in particular there is
a marked increase in intensity of nuclear staining following
tamoxifen treatment (Figures 5a and b). Taken together,
these data illustrate that tamoxifen treatment of primary
breast cancer fibroblasts increases the extent of TGF-fl,
immunoreactivity but, unusually, this staining appears
largely confined to the nucleus.
Discussion
Recent in vivo studies demonstrating induction of extra-
cellular TGF-/3, by tamoxifen in both ER-positive and ER-
negative patients provide strong evidence in support of
negative paracrine regulation of breast cancer. Increased
immunoreactive TGF-/3, was observed between and around
stromal cells with little increase in the vicinity of epithelial
cells. Moreover, staining for the intracellular form of the
Figure 3 (a-c) Staining of breast tumour fibroblasts for the
intracellular (LC) form of TGF-f31. Fibroblasts were grown to
subconfluence in slide flasks and exposed to either tamoxifen or
vehicle for 48h before staining with the anti-LC antibody to the
intracellular form ofTGF-fl1. This primary antibody was detected
with a secondary antibody conjugated to the immunofluorescent
marker Texas red. (a) Cells treated with ethanolic vehicle followed
by staining with anti-LC antibody. (b) Cells treated with
tamoxifen (1000nM) for 48h before staining with anti-LC
antibody. (c) Cells stained with rabbit IgG only as a primary
antibody control. Staining for TGF-f3, was predominantly
distributed in the region of the nucleus, with no nuclear staining
being seen with the control (rabbit IgG) antibody. This nuclear
staining is dramatically increased following tamoxifen treatment
of cells (b).
peptide was largely confined to stromal cells (Butta et al.,
1992). These findings are consistent with the hypothesis that
stromal fibroblasts are directly stimulated to produce and
secrete a negative growth modulator that acts upon
neighbouring epithelial cells in a paracrine manner. The
data also suggest a potential role for the extracellular matrix
in 'recruiting' newly synthesised TGF-3,B adjacent to the
tumour epithelium.
The preservation of tissue organisation in these immuno-
histochemical studies is a great advantage over in vitro studies
_Tamoxifen and TGF-,B isoforms
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Figure 4 Intracellular localisation ofTGF-f31 immunofluorescent staining offibroblasts using confocal microscopy in which optical
sections of 0.1 m thickness were taken sequentially through the image plane at 1 pm intervals. Immunofluorescence is maximal in
the central portion of the cell nucleus, and this confirms that staining is nuclear and not perinuclear.
Figure 5 (a and b) Further characterisation of intracellular
staining for TGF-fl1 using an antibody to the precursor region of
TGF-f,3 (amino acids 266-278). This primary antibody was also
detected with a secondary antibody conjugated to the immuno-
fluorescent marker Texas red. (a) Cells treated with ethanolic
vehicle followed by staining with precursor antibody. (b) Cells
treated with tamoxifen (1000nM) for 48h before staining with
precursor antibody. This antibody to the precursor region of
TGF-fl1 demonstrates an essentially similar pattern of staining to
the anti-LC antibody, although there appears to be greater
cytoplasmic staining. Following exposure to tamoxifen, this
nuclear staining is markedly increased (b) compared with control
cells (a), and this co-localisation confirms that this staining is
attributable to TGF-31.
on isolated cellular components. However, only an in vitro
system can unequivocally demonstrate secretion of a
substance by a particular cell type. The in vitro experiments
reported here show that fibroblasts derived from both benign
and malignant breast tumours produce and secrete relatively
high levels of TGF-f,B. There is no statistically significant
difference in levels of TGF-Pf secretion between malignant
and benign breast tumour fibroblasts, but the latter produce
significantly higher levels of TGF-fi2 (P<0.05). This may
indicate that differential quantitative expression of TGF-f
isoforms is important during neoplastic development.
Absolute levels of TGF-f, are on average 3-to 4-fold higher
than baseline unstimulated levels in fetal fibroblasts in which
maximal induction ranged from 3-to 30-fold (Colletta et al.,
1990). However, contrary to any anticipation based on
previous in vitro (Colletta et al., 1990) and in vivo (Butta et
al., 1992) studies, tamoxifen did not induce any consistent
increase in secreted levels of TGF-fl, from these isolated
breast tumour fibroblasts. Only one fibroblast strain (A)
derived from a malignant tumour showed a modest increase
in TGF-fl1 in response to tamoxifen.
Tamoxifen may increase the synthesis of TGF-f13 in these
breast tumour fibroblasts, but because of their isolation from
neighbouring malignant epithelial cells in vitro, any increased
secretion secondary to enhanced production of TGF-fhl is
abrogated. This interpretation is supported by results of
staining for the intracellular form of TGF-Pf, demonstrating
increased synthesis of TGF-11 in response to tamoxifen.
However, co-culture of breast tumour fibroblasts with ER-
negative breast carcinoma cells (BT-20) in a monolayer
system has failed to restore any significant secretory response
by fibroblasts (our unpublished observations), and more
sophisticated 3-D systems may be required to achieve this.
The immunofluorescence data in Figures 3 and 5 reveal
that staining for both TGF-f31 and the precursor peptide
occurs predominantly in the nuclear region with much
weaker cytoplasmic staining. This unusual, but provocative,
finding suggests that TGF-,B has distinct intracellular
localisations. Moreover, two discrete forms of intracellular
TGF-fh may exist - a secreted and a nuclear form. Like
many other growth factors, TGF-1 is considered to act
classically by interaction with cell-surface receptors, and
subsequent activation of intracellular transduction pathways.
However, recent evidence challenges this as an exclusive
phenomenon for mediating the action of certain growth
factors (Cross and Dexter, 1991). Cells may produce growth
factors and related proteins that are not only destined for
secretion, but that may also be diverted to the nucleus where
they can directly influence nuclear events independently of
any cognate receptor. The int-2 gene appears to encode two
similar products, but with different subcellular fates. One
protein enters the secretory pathway, whereas an N-
terminally extended protein is diverted to the nucleusTamoxifen and TGF-,B isoforms
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(Acland et al., 1990). Other examples of nuclear localisation
of common growth factors such as epidermal growth factor
and colony-stimulating factor 1 have been reported (Johnson
et al., 1980; Yeh et al., 1987; Scholl et al., 1994).
Therefore, fibroblasts may produce two forms of TGF-f3,
one of which is destined for secretion and will act
extracellularly via membrane receptors, and a second form
that is localised/translocated to the nucleus. These secretory
and nuclear forms of TGF-/31 could be differentially induced
by tamoxifen. Relative amounts of the secretory form of
TGF-P1 may be increased by tamoxifen in vivo (Butta et al.,
1992), but isolated fibroblasts in vitro may respond aberrantly
to tamoxifen with increased amounts of the nuclear form.
Attempts to determine the molecular mass of the cytoplasmic
and nuclear forms of TGF-f31 by immunoblotting using the
above antibodies were unsuccessful.
Control of the relative amounts of secretory and nuclear
forms of TGF-f,3 may occur at the level of translation of the
TGF-/3, mRNA molecule. By analogy with the prostatic
protein, probasin (Spence et al., 1989), both nuclear and
secretory forms of TGF-3,1 could be encoded by a single
mRNA molecule as a second 'in-phase' initiation codon exists
within the coding region of the TGF-3,1 mRNA molecule that
has a better sequence context for translational initiation
(Derynck et al., 1985). Initiation from the downstream AUG
would result in a smaller TGF-f precursor (354 amino-acids)
and eliminate the signal peptide sequence that might allow
trafficking to intracellular locations such as the nucleus.
This increased intracellular staining for TGF-fl following
tamoxifen treatment was also found in cells stained with anti-
LC antibody and a secondary biotinylated antibody linked to
a peroxidase-labelled avidin-biotin system. Furthermore, this
response was observed in fibroblasts derived from both
benign and malignant breast tumours, but not normal skin
fibroblasts (data not shown). These findings suggest that
fibroblasts from both benign and malignant tumours may
display phenotypic features that are not shared by other
somatic fibroblasts, and may be acquired during the process
of neoplastic development. That phenotypic differences may
exist between breast tumour fibroblasts and 'normal'
fibroblasts is supported by the findings that conditioned
media from benign and malignant breast tumours is
stimulatory to MCF-7 cells in vitro, whereas media from
normal skin fibroblasts is inhibitory to these cells (Adams et
al., 1988). Aberrant stromal phenotypes in breast tumours
may lead to deranged stromal-epithelial interactions and
promote neoplastic progression.
Increased synthesis of TGF-/31 is not associated with any
concomitant elevation of mRNA levels in MCF-7 breast
cancer cells (Knabbe et al., 1987) or fetal fibroblasts (Colletta
et al., 1990). We have similar data from breast tumour
fibroblasts in vitro (data not shown), and tamoxifen would
therefore appear to enhance synthesis at a post-transcrip-
tional level, although transcriptional mechanisms may also be
operative depending on the local tissue levels of tamoxifen
(Perry et al., 1995; Benson and Baum, 1996) and TGF-#
isoform type (Arrick et al., 1994; MacCallum et al., 1994).
The results of these in vitro investigations corroborate
previous in vivo studies demonstrating induction of stromal
TGF-fl, by tamoxifen. In particular, they confirm that breast
tumour fibroblasts are a potential source of TGF-fl1, and
despite limitations of in vitro data, evidence is presented for a
direct effect of tamoxifen upon tumour fibroblasts in the
absence of measurable oestrogen receptor. However, such
induction of TGF-3,1 may not be a property unique to
tamoxifen. Recently, up-regulation of extracellular TGF-,B
has been observed in prostate cancer patients following
various forms of ablative androgen therapy (Muir et al.,
1994). Therefore, TGF-# induction may be a common step in
several therapeutic interventions which may not involve
classical hormone receptors.
The challenge for the future is to develop agents that can
modulate fibroblast behaviour, and are of a specificity and
potency that renders them clinically efficacious. Such a
strategy may be especially pertinent in a chemopreventive
setting and in early-stage malignancies in which tumour
burden is modest and cells still possess appropriate receptors
for negative growth modulators such as TGF-f,.
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